Silodosin Impurity 13

Development of Stability-Indicating UHPLC Method for the Quantitative Determination of Silodosin and Its Related Substances
Jafer Vali Shaik, Shantikumar Saladi, Shakil S. Sait
Journal of Chromatographic Science, Volume 52, Issue 7, August 2014, Pages 646–653
 
Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry
Sukanya Pandeti  Tadigoppula Narender  Sripadi Prabhakar  Thota Jagadeswar Reddy
Rapid Communications in Mass Spectrometry Volume31, Issue6 30 March 2017 Pages 572-582
 
Development and Validation of High Performance LCMS Methods for Estimation of Silodosin and Silodosin β-D-Glucuronide in Human Plasma
Sheeba Manoj Nair1 *, Ravi Kumar P1 , Malini Sharma1 and Denish Karia
Nair et al., Pharm Anal Chem 2016, 3:1
 
An effective and sensitive stability-indicating chromatographic approach based on HPLC for silodosin assay
Engin Er & Nevin Erk
Journal of Analytical Science and Technology volume 7, Article number: 20 (2016)

Silodosin Impurity 13 is chemically 3-{7-Cyano-5-[(2R)-2-(2,2,2-trifluoroethoxy)-phenoxy]-ethyl}amino)-propyl]-2,3-dihydro-1H indol-1-yl]-propyl benzoate. Silodosin Impurity 13 is supplied with detailed characterization data compliant with regulatory guideline. Silodosin Impurity 13 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Silodosin.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.